Differential effects of myosin activators on myocardial contractile function in nonfailing and failing human hearts
The second-generation myosin activator danicamtiv (DN) has shown improved function
compared with the first-generation myosin activator omecamtiv mecarbil (OM) in nonfailing …
compared with the first-generation myosin activator omecamtiv mecarbil (OM) in nonfailing …
Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium
Background Omecamtiv mecarbil (OM) and danicamtiv both increase myocardial force
output by selectively activating myosin within the cardiac sarcomere. Enhanced force …
output by selectively activating myosin within the cardiac sarcomere. Enhanced force …
cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation
Omecamtiv mecarbil (OM), a direct myosin motor activator, is currently being tested as a
therapeutic replacement for conventional inotropes in heart failure (HF) patients. It is known …
therapeutic replacement for conventional inotropes in heart failure (HF) patients. It is known …
Prof. Cristobal dos Remedios and the Sydney Heart Bank: enabling translatable heart failure research
JB Holmes, JE Stelzer - Biophysical Reviews, 2020 - Springer
Thanks in large part to the pioneering efforts of Prof. Cristobal dos Remedios and the
Sydney Heart Bank (SHB), accessible donor and diseased human heart tissue has become …
Sydney Heart Bank (SHB), accessible donor and diseased human heart tissue has become …